de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Four antibiotic compounds produced in Streptomyces bacteria attack multiple parts of an essential metabolic pathway.

As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

The Department of Health and Human Services has announced funding for antibiotic research and development using Generative AI. The stop Emerging Threats (TARGET), through the Advanced Research ...

Wockhardt's Zaynich has received US FDA approval, becoming India's first indigenously developed novel antibiotic approved in ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

Scientists from the University of Illinois Chicago and Harvard University have announced the development of a potent new antibiotic that could revolutionize the fight against drug-resistant bacteria.